DOI Prefix : 10.9780 | Journal DOI : 10.9780/22307850
Scroll to Top

Volume : III, Issue : III, April - 2013

PROMISES OF INDUCED PLURIPOTENT STEM CELLS IN A THERAPEUTIC CONTEXT

HIMANSU KUMAR AND C.V.S.SIVA PRASAD

DOI : 10.9780/22307850, Published By : Laxmi Book Publication

Abstract :

Transformation of somatic cells into induced pluripotent stem cells (IPSC) has opened a new page in the clinical world. In 2006, Yamanaka and Takahashi have shown that the four reprogramming factors namely OCT4, NANOG, SOX2, and LIN28 are sufficient for the reprogramming of somatic cells into IPSC. Fortunately these IPSC are containing all essential features of embryonic stem cells and finally it leads to specific tissue regeneration. Although there are certain limitations of IPSC like low efficiency of IPSC generation, reprogramming process is highly time consuming and viral vector based delivery of transcription factors into target may induce mutations in the genome. In this review we would like to focus on comprehensive knowledge about IPSC, derivation mechanism of IPSC, clinical application of IPSC and technical challenges for the implementation of the IPSC into biomedical and therapeutic applications.

Keywords :


Article :


Cite This Article :

HIMANSU KUMAR AND C.V.S.SIVA PRASAD, (2013). PROMISES OF INDUCED PLURIPOTENT STEM CELLS IN A THERAPEUTIC CONTEXT. Indian Streams Research Journal, Vol. III, Issue. III, DOI : 10.9780/22307850, http://oldisrj.lbp.world/UploadedData/2290.pdf

References :

  1. 1.Tuch BE (2006). "Stem cells—a clinical update". Australian Family Physician 35 (9): 719–21. PMID 16969445.
  2. 2.Takahashi K, Yamanaka S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell 126 (4): 663–76.
  3. 3.Kaplan, Karen (2009-03-06). "Cancer threat removed from stem cells, scientists say". Los Angeles Times.
  4. 4.Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS (27 May 2009). "Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins". Cell Stem Cell 4 (6): 472–6.
  5. DOI:10.1016/j.stem.2009.05.005. PMC 2705327. PMID 19481515. Lay summary. 5."First trial of embryonic stem cells in humans". BBC News. 2010-10-11.
  6. 6.Fulka J Jr. First NL, Loi P, Moor RM. Cloning by somatic cell nuclear transfer. Bioessays 1998;20(10):847–851. [PubMed: 9819572]
  7. 7.Agarwal S. Cellular reprogramming. Methods Enzymol 2006;420:265–283. [PubMed: 17161701]
  8. 8.Krishanu Saha and Rudolf Jaenisch (2009), “Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease.” DOI 10.1016/j.stem.2009.11.009
  9. 9.Flasza M, Shering AF, Smith K, Andrews PW, Talley P, Johnson PA. Reprogramming in interspecies embryonal carcinoma-somatic cell hybrids induces expression of pluripotency and differentiation markers. Cloning Stem Cells 2003;5(4):339–354. [PubMed: 14733752]
  10. 10.Taranger CK, Noer A, Sorensen AL, Hakelien AM, Boquest AC, Collas P. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell 2005;16(12):5719–5735. [PubMed: 16195347]
  11. 11.H. Park, N. Arora, H. Huo et al., “Disease-specific induced pluripotent stem cells,” Cell, vol. 134, no. 5, pp. 877–886, 2008.
  12. 12.F. Soldner, D. Hockemeyer, C. Beard et al., “Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors,” Cell, vol. 136, no. 5, pp. 964– 977, 2009.
  13. 13.H. Zhou, S. Wu, J. Y. Joo et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, vol. 4, no. 5, pp. 381–384, 2009
  14. 14.J. T. Dimos, K. T. Rodolfa, K. K. Niakan et al., “Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons,” Science, vol. 321, no. 5893, pp. 1218–1221, 2008.
  15. 15.O. Cooper, G. Hargus, M. Deleidi et al., “Differentiation of human ES and parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid,” Molecular and Cellular Neuroscience, vol. 45, no. 3, pp. 258–266, 2010
  16. 16.G. Hargus, O. Cooper, M. Deleidi et al., “Differentiated parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in parkinsonian rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15921–15926, 2010.
  17. 17.N. Zhang,, M. C. An, D. Montoro, and L. M. Ellerby, “Characterization of human Huntington's disease cell model from induced pluripotent stem cells,” PLoS Currents, vol. 2, Article ID RRN1193, 2010
  18. 18.A. Hotta, A. Y. L. Cheung, N. Farra et al., “Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency,” Nature Methods, vol. 6, no. 5, pp. 370–376, 2009
  19. 19.G. Lee, E. P. Papapetrou, H. Kim et al., “Modelling pathogenesis and treatment of familial dysautonomia using patientspecific iPSCs,” Nature, vol. 461, no. 7262, pp. 402–406, 2009.
  20. 20.S. J. Chamberlain, P. F. Chen, K. Y. Ng et al., “Induced pluripotent stem cell models of the genomic imprinting disorders angelman and prader-willi syndromes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 41, pp. 17668 17673, 2010.
  21. 21.J. Yang, J. Cai, Y. Zhang et al., “Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome,” The Journal of Biological Chemistry, vol. 285, no. 51, pp. 40303–40311, 2010.
  22. 22.S. Ku, E. Soragni, E. Campau et al., “Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability,” Cell Stem Cell, vol. 7, no. 5, pp. 631–637, 2010.
  23. 23.M. C. N. Marchetto, C. Carromeu, A. Acab et al., “A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells,” Cell, vol. 143, no. 4, pp. 527–539, 2010.
  24. 24.K. J. Brennand, A. Simone, J. Jou et al., “Modelling schizophrenia using human induced pluripotent stem cells,” Nature, vol. 473, no. 7346, pp. 221–225, 2011.
  25. 25.A. Somers, J. C. Jean, C. A. Sommer et al., “Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette,” Stem Cells, vol. 28, no. 10, pp. 1728–1740, 2010.
  26. 26.I. M. Pessach, J. Ordovas-Montanes, S. Y. Zhang et al., “Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies,” Journal of Allergy and Clinical Immunology, vol. 127, no. 6, pp. 1400–1407, 2011.
  27. 27.Y. Kazuki, M. Hiratsuka, M. Takiguchi et al., “Complete genetic correction of ips cells from duchenne muscular dystrophy,” Molecular Therapy, vol. 18, no. 2, pp. 386–393, 2010.
  28. 28.Y. Wang, Y. Jiang, S. Liu, X. Sun, and S. Gao, “Generation of induced pluripotent stem cells from human â-thalassemia fibroblast cells,” Cell Research, vol. 19, no. 9, pp. 1120–1123, 2009.
  29. 29.L. Ye, J. C. Chang, C. Lin, X. Sun, J. Yu, and Y. W. Kan, “Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 24, pp. 9826–9830, 2009.
  30. 30.J. E. Carette, J. Pruszak, M. Varadarajan et al., “Generation of iPSCs from cultured human malignant cells,” Blood, vol. 115, no. 20, pp. 4039–4042, 2010
  31. 31.A. Moretti, M. Bellin, A. Welling et al., “Patient-specific induced pluripotent stem-cell models for long- QT syndrome,” New England Journal of Medicine, vol. 363, no. 15, pp. 1397 1409, 2010.
  32. 32.I. Itzhaki, L. Maizels, I. Huber et al., “Modelling the long QT syndrome with induced pluripotent stem cells,” Nature, vol. 471, no. 7337, pp. 225–239, 2011
  33. 33.R. Maehr, S. Chen, M. Snitow et al., “Generation of pluripotent stem cells from patients with type 1 diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15768–15773, 2009.
  34. 34.X. Carvajal-Vergara, A. Sevilla, S. L. D'Souza et al., “Patientspecific induced pluripotent stem-cellderived models of LEOPARD syndrome,” Nature, vol. 465, no. 7299, pp. 808– 812, 2010
  35. 35.J. Tolar, I. H. Park, L. Xia et al., “Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome),” Blood, vol. 117, no. 3, pp. 839–847, 2011.
  36. 36.A. Raya, I. Rodriguez-Piz, G. Guenechea et al., “Diseasecorrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells,” Nature, vol. 460, no. 7251, pp. 53–59, 2009.
  37. 37.S. T. Rashid, S. Corbineau, N. Hannan et al., “Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells,” Journal of Clinical Investigation, vol. 120, no. 9, pp. 3127–3136 2010
  38. 38.A. Urbach, O. Bar-Nur, G. Q. Daley, and N. Benvenisty, “Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells,” Cell Stem Cell, vol. 6, no. 5, pp. 407–411, 2010.
  39. 39.S. Agarwal, Y. H. Loh, E. M. McLoughlin et al., “Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients,” Nature, vol. 464, no. 7286, pp. 292– 296, 2010.
  40. 40.Z. B. Jin, S. Okamoto, F. Osakada et al., “Modeling retinal degeneration using patient specific induced pluripotent stem cells,” PloS One, vol. 6, no. 2, Article ID e17084, 2011.
  41. 41.J. S. Meyer, S. E. Howden, K. A.Wallace et al., “Optic vesiclelike structures derived from human pluripotent stem cells facilitate a customized approach to retinal disease treatment,” Stem Cells, vol. 29, no. 8, pp. 1206–1218, 2011.
  42. 42.Loh YH, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC, et al. Generation of induced pluripotent stem cells from human blood. Blood. 2009.
  43. 43.Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448(7151): 313-7.
  44. 44.Pan G, Tian S, Nie J, et al. Whole-genome analysis of histone H3 lysine 4 and lysine 27 methylation in human embryonic stem cell. Cell Stem Cell 2007; 1(3): 299-312.

Article Post Production

Article Indexed In

Comments :
Enter Name :
Email ID :
Comments :

Previous Comments :
Creative Commons License
Indian Streams Research Journal by Laxmi Book Publication is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://oldisrj.lbp.world/Default.aspx.
Permissions beyond the scope of this license may be available at http://oldisrj.lbp.world/Default.aspx
Copyright © 2014 Indian Streams Research Journal. All rights reserved
Looking for information? Browse our FAQs, tour our sitemap, or contact ISRJ
Read our Privacy Policy Statement and Plagairism Policy. Use of this site signifies your agreement to the Terms of Use